LCZ696 is anticipated to become a core therapy for HFrEF, with clinical implementation guided by the PARADIGM-HF trial protocol.
May inform LCZ696 initiation in HFrEF per PARADIGM-HF; leaves open real-world applicability and long-term data.
Speculation that LCZ696 will pass the scrutiny of regulatory agencies for HF-REF appears to be justified, and it is likely to become a core therapeutic component in the near future. Replication of the eligibility criteria and titration protocol used in the PARADIGM-HF trial would be valuable in clinical practice and may minimize the risk of adverse events. Although long-term data remain to be generated, the promising results regarding hypertension are likely to expedite acceptance of the drug for HF-REF.
No takes yet. Share an insight, caveat, or question.
Minguet et al. (2015) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: